Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.8333.

PYXS has been the subject of several research analyst reports. Stifel Nicolaus decreased their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Wedbush assumed coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.80 on Monday. The company has a 50 day moving average price of $1.79 and a 200-day moving average price of $2.16. Pyxis Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $5.55. The company has a market capitalization of $114.03 million, a PE ratio of -1.37 and a beta of 1.42.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, analysts forecast that Pyxis Oncology will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after buying an additional 160,300 shares during the period. J. Derek Lewis & Associates Inc. purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $61,000. XTX Topco Ltd increased its holdings in Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock valued at $332,000 after buying an additional 271,334 shares during the period. Toronto Dominion Bank purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $86,000. Finally, Quadrature Capital Ltd purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $116,000. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.